Secondary MDS/AML in Women After Chemotherapy | Aplastic Anemia & MDS International Foundation

Secondary MDS/AML in Women After Chemotherapy

Topic(s): 
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presentation Date: 
Wednesday, August 19, 2020

Kathleen Moore, MD is Director, Oklahoma TSET Phase I Program; Associate Professor, Section of Gynecologic Oncology and is an associate professor in the section of gynecologic oncology and serves as the director of the Oklahoma TSET Phase I Clinical Trials Program, the state’s only phase I clinical trials program. She is the Jim and Christy Everest Endowed Chair in Cancer Research as well as the director of the gynecologic oncology fellowship program. She also serves as the Associate Director of Clinical Research and Medical Director of the Clinical Trials Office for the Stephenson Cancer Center. 

Dr. Moore discusses the unique concerns of female patients who develop Secondary MDS/AML after chemotherapy treatment.  This session includes current treatment options as well as a review of what is currently in clinical trial, including Dr. Moore's own work in drug development.